查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600101

肝肾综合症治疗市场：按类型、治疗方法和最终用户划分 - 全球预测 2025-2030

Hepatorenal Syndrome Treatment Market by Type (Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome), Treatment (Surgical Treatment, Therapeutics), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年肝肾症候群治疗市值为45.6亿美元，预计2024年将达48亿美元，复合年增长率为5.47%，预计到2030年将达到66.2亿美元。

肝肾症候群 (HRS) 治疗的重点是治疗晚期肝病患者的一种复杂病症，其特征是肾臟迅速恶化。这些包括血管收缩剂和白蛋白等药物、透析治疗、肝臟移植和新生技药品。需要 HRS 治疗是因为这种情况与高发病率和死亡率相关，早期有效的干预对于改善患者的预后至关重要。 HRS治疗适用于医院、诊所和研究机构，主要针对肝硬化或等待肝臟移植的患者。对 HRS 治疗市场的见解突显了全球肝病发病率的上升、治疗方法的进步以及接受移植的患者数量不断增加所推动的显着增长。然而，它们面临着治疗成本上升、移植器官供应有限以及阻碍新治疗方法核准过程的监管挑战等限制。就商业机会而言，提供标靶治疗解决方案的新型生物标记和治疗方法市场的开拓前景。製药公司和研究机构之间的合作研究可以加速药物发现并加强治疗策略。对研发和适应性临床试验设计的投资可以导致个人化治疗计划的製定，这也有可能改善患者特定的结果。鼓励市场相关人员专注于生技药品和再生医学的创新，鑑于未满足的需求，这提供了一条有希望的道路。我们面临的挑战是应对严格的监管环境并解决治疗的可负担性问题，这需要策略定价和更强有力的卫生政策以确保广泛获得治疗。认识到新兴市场的多面性，公司正在探索与数位健康公司建立合作伙伴关係，以开发平台并利用资料来实现更好的疾病管理和患者对治疗方法的依从性并改善健康结果。

主要市场统计
基准年[2023] 45.6亿美元
预测年份 [2024] 48亿美元
预测年份 [2030] 66.2亿美元
复合年增长率（%） 5.47%

市场动态：快速发展的肝肾症候群治疗市场的关键市场洞察

供需的动态交互作用正在改变肝肾综合症治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 肝肾综合症盛行率增加
    • 快速通道和孤儿药指定的增加
    • 提高疾病意识和患者支持计划
  • 市场限制因素
    • 处理成本高，产品召回事故频传
  • 市场机会
    • 增加尖端技术的研发
    • 增加专注于创新 HRS 治疗的生物创投公司的资金和创业投资
  • 市场挑战
    • 与药物使用相关的副作用和风险

波特五力：驾驭肝肾症候群治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解肝肾症候群治疗市场的外部影响

外部宏观环境因素在塑造肝肾症候群治疗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解肝肾症候群治疗市场的竞争状况

肝肾综合症治疗市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵肝肾症候群治疗市场供应商的绩效评估

FPNV定位矩阵是评估肝肾症候群治疗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製肝肾综合症治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对肝肾综合征治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 肝肾综合症盛行率增加
      • 简审类和孤儿药指定的增加
      • 扩大疾病意识和患者支持计划
    • 抑制因素
      • 高额处理成本和产品召回事件
    • 机会
      • 加强研发，融入先进技术
      • 增加对专注于创新 HRS 治疗的生物技术新兴企业的资金和创业投资
    • 任务
      • 与药物使用相关的副作用和风险
  • 市场区隔分析
    • 治疗：持续创新以提高手术介入的有效性和治疗结果
    • 最终用户：医院和诊所提供全面的医疗保健解决方案和服务
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章肝肾症候群治疗市场：依类型

  • 1型肝肾综合症
  • 2型肝肾综合症

第七章肝肾症候群治疗市场（依治疗）

  • 手术治疗
    • 肝臟移植
    • 肾臟替代治疗
    • 手术分流术
  • 治疗药物
    • 甘加压素
    • 卢卡辛
    • 特尔里瓦兹

第八章肝肾症候群治疗市场：依最终用户分类

  • 学术研究所
  • 门诊手术中心
  • 医院/诊所

第九章北美及南美肝肾症候群治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太肝肾症候群治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲/中东/非洲肝肾症候群治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Mallinckrodt在SCCM 2023会议上展示TERLIVAZ改善肝肾症候群的重要研究成果
    • FDA核准首个治疗肝肾症候群快速肾衰竭的药物
  • 战略分析和建议

公司名单

  • Aetna Inc.
  • Baxter International Inc
  • Becton, Dickinson and Company
  • Biocon Limited
  • BioVie Inc
  • Cadila Healthcare Limited
  • Cumberland Pharmaceuticals Inc
  • Edwards Lifesciences Corporation
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Mallinckrodt Inc
  • Medtronic plc
  • Neovii Pharmaceuticals AG
  • Novartis International AG
  • Orphan Therapeutics, LLC
  • PharmaIN Corporation
  • Samarth Life Sciences Pvt Ltd.
  • Swastik Life Sciences
  • United Biotech Pvt Ltd.
Product Code: MRR-035DA3C63700

The Hepatorenal Syndrome Treatment Market was valued at USD 4.56 billion in 2023, expected to reach USD 4.80 billion in 2024, and is projected to grow at a CAGR of 5.47%, to USD 6.62 billion by 2030.

Hepatorenal syndrome (HRS) treatment is focused on managing a complex condition characterized by rapid kidney deterioration in individuals with advanced liver disease. The scope includes pharmaceutical therapies such as vasoconstrictors and albumin, dialysis modalities, liver transplants, and emerging biologics. The necessity of HRS treatment arises due to the condition's association with high morbidity and mortality rates, making early and effective intervention critical in improving patient outcomes. Its application spans across hospital settings, clinics, and research institutions, primarily targeting patients with conditions like cirrhosis and those awaiting liver transplants. Insights into the HRS treatment market highlight substantial growth propelled by an increase in liver diseases globally, advancements in therapeutic methods, and a growing transplant recipient population. However, the market faces limitations, such as the high cost of treatment, limited availability of transplant organs, and regulatory challenges that hinder approval processes for new therapies. In terms of opportunity, the market holds potential in the development of novel biomarkers and therapies that offer targeted treatment solutions. Collaborations between pharmaceutical companies and research organizations can accelerate drug discovery and enhance therapeutic strategies. Investment in R&D and adaptive clinical trial designs could also lead to the development of personalized treatment plans, improving patient-specific outcomes. Market players are recommended to focus on innovation in biologics and regenerative medicines, which present promising avenues given the unmet clinical needs. Challenges lay in navigating the stringent regulatory landscapes and addressing the affordability of treatments, which require strategic pricing and enhanced healthcare policies to facilitate widespread accessibility. Recognizing the multidimensional nature of the market, businesses should also explore partnerships with digital health companies to develop platforms that allow for better disease management and patient adherence to therapy regimens, leveraging data for improved health outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 4.56 billion
Estimated Year [2024] USD 4.80 billion
Forecast Year [2030] USD 6.62 billion
CAGR (%) 5.47%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hepatorenal Syndrome Treatment Market

The Hepatorenal Syndrome Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of hepatorenal syndrome
    • Increasing fast track and orphan drug designations
    • Growing disease awareness & patient support programs
  • Market Restraints
    • High treatment costs, and product recall incidents
  • Market Opportunities
    • Increasing research & development to incorporate advanced technologies
    • Increased funding and venture capital for biotech start-ups focusing on innovative HRS treatments
  • Market Challenges
    • Side-effects and risks related to drug usage

Porter's Five Forces: A Strategic Tool for Navigating the Hepatorenal Syndrome Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hepatorenal Syndrome Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hepatorenal Syndrome Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hepatorenal Syndrome Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hepatorenal Syndrome Treatment Market

A detailed market share analysis in the Hepatorenal Syndrome Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hepatorenal Syndrome Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hepatorenal Syndrome Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hepatorenal Syndrome Treatment Market

A strategic analysis of the Hepatorenal Syndrome Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hepatorenal Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include Aetna Inc., Baxter International Inc, Becton, Dickinson and Company, Biocon Limited, BioVie Inc, Cadila Healthcare Limited, Cumberland Pharmaceuticals Inc, Edwards Lifesciences Corporation, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Mallinckrodt Inc, Medtronic plc, Neovii Pharmaceuticals AG, Novartis International AG, Orphan Therapeutics, LLC, PharmaIN Corporation, Samarth Life Sciences Pvt Ltd., Swastik Life Sciences, and United Biotech Pvt Ltd..

Market Segmentation & Coverage

This research report categorizes the Hepatorenal Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Type 1 Hepatorenal Syndrome and Type 2 Hepatorenal Syndrome.
  • Based on Treatment, market is studied across Surgical Treatment and Therapeutics. The Surgical Treatment is further studied across Liver Transplantation, Renal Replacement Therapy, and Surgical Shunting. The Therapeutics is further studied across Glypressin, Lucassin, and Terlivaz.
  • Based on End-User, market is studied across Academic & Research Institutes, Ambulatory Surgical Centers, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of hepatorenal syndrome
      • 5.1.1.2. Increasing fast track and orphan drug designations
      • 5.1.1.3. Growing disease awareness & patient support programs
    • 5.1.2. Restraints
      • 5.1.2.1. High treatment costs, and product recall incidents
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing research & development to incorporate advanced technologies
      • 5.1.3.2. Increased funding and venture capital for biotech start-ups focusing on innovative HRS treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Side-effects and risks related to drug usage
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Ongoing innovations to improve the efficacy and treatment outcomes of surgical interventions
    • 5.2.2. End-User: Availability of comprehensive healthcare solutions and services in hospitals and clinics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hepatorenal Syndrome Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Type 1 Hepatorenal Syndrome
  • 6.3. Type 2 Hepatorenal Syndrome

7. Hepatorenal Syndrome Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Surgical Treatment
    • 7.2.1. Liver Transplantation
    • 7.2.2. Renal Replacement Therapy
    • 7.2.3. Surgical Shunting
  • 7.3. Therapeutics
    • 7.3.1. Glypressin
    • 7.3.2. Lucassin
    • 7.3.3. Terlivaz

8. Hepatorenal Syndrome Treatment Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Ambulatory Surgical Centers
  • 8.4. Hospitals & Clinics

9. Americas Hepatorenal Syndrome Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Hepatorenal Syndrome Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Hepatorenal Syndrome Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Mallinckrodt Announces Key Study Results on TERLIVAZ for Hepatorenal Syndrome Reversal at SCCM 2023 Congress
    • 12.3.2. FDA Approves First-Ever Treatment for Rapid Kidney Failures in Hepatorenal Syndrome
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aetna Inc.
  • 2. Baxter International Inc
  • 3. Becton, Dickinson and Company
  • 4. Biocon Limited
  • 5. BioVie Inc
  • 6. Cadila Healthcare Limited
  • 7. Cumberland Pharmaceuticals Inc
  • 8. Edwards Lifesciences Corporation
  • 9. F. Hoffmann-La Roche AG
  • 10. GlaxoSmithKline plc
  • 11. Mallinckrodt Inc
  • 12. Medtronic plc
  • 13. Neovii Pharmaceuticals AG
  • 14. Novartis International AG
  • 15. Orphan Therapeutics, LLC
  • 16. PharmaIN Corporation
  • 17. Samarth Life Sciences Pvt Ltd.
  • 18. Swastik Life Sciences
  • 19. United Biotech Pvt Ltd.

LIST OF FIGURES

  • FIGURE 1. HEPATORENAL SYNDROME TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HEPATORENAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HEPATORENAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEPATORENAL SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEPATORENAL SYNDROME TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE 1 HEPATORENAL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE 2 HEPATORENAL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY RENAL REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL SHUNTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GLYPRESSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY LUCASSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TERLIVAZ, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. HEPATORENAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 235. HEPATORENAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023